

# Qaiser Bashir

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4352536/publications.pdf>

Version: 2024-02-01

291  
papers

4,080  
citations

159358

30  
h-index

155451

55  
g-index

293  
all docs

293  
docs citations

293  
times ranked

5205  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiotoxicity of Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 7685-7696.	0.8	315
2	Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1835-1844.	2.0	227
3	Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen-Matched Unrelated and Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1975-1981.	2.0	207
4	Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 177, 457-466.	1.2	158
5	Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. <i>Blood</i> , 2015, 125, 2885-2892.	0.6	118
6	Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. <i>British Journal of Haematology</i> , 2016, 174, 235-248.	1.2	115
7	Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation with Sorafenib. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1874-1877.	2.0	97
8	Nonmyeloablative allogeneic transplantation with or without <sup>90</sup> yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. <i>Blood</i> , 2012, 119, 6373-6378.	0.6	97
9	Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 344-356.	2.0	90
10	Results of a phase 2 clinical trial using posttransplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. <i>Cancer</i> , 2016, 122, 3316-3326.	2.0	75
11	Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2012, 53, 118-122.	0.6	74
12	Durable remission with salvage second autotransplants in patients with multiple myeloma. <i>Cancer</i> , 2012, 118, 3549-3555.	2.0	69
13	Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e266-e275.	2.2	68
14	Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1232-1236.	2.0	64
15	Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. <i>Blood</i> , 2018, 131, 2989-2992.	0.6	63
16	Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 410-417.	2.0	61
17	Posttransplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2016, 173, 444-455.	1.2	61
18	Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1514-1520.	2.0	61

#	ARTICLE	IF	CITATIONS
19	Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. <i>British Journal of Haematology</i> , 2018, 182, 916-920.	1.2	59
20	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. <i>British Journal of Haematology</i> , 2017, 179, 781-789.	1.2	56
21	Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 110-117.	1.7	54
22	Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. <i>Cancer</i> , 2016, 122, 2680-2688.	2.0	48
23	Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1914-1920.	2.0	46
24	High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1677-1686.	2.0	43
25	Decrease post-transplant relapse using donor-derived expanded NK-cells. <i>Leukemia</i> , 2022, 36, 155-164.	3.3	43
26	Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. <i>Blood</i> , 2020, 136, 1786-1789.	0.6	40
27	A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. <i>Cancer</i> , 2012, 118, 2507-2515.	2.0	39
28	Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?. <i>Blood</i> , 2020, 135, 449-452.	0.6	39
29	Chromosome 8q24.1 c-MYC abnormality: a marker for high-risk myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 602-607.	0.6	38
30	Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1227-1232.	2.0	34
31	Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2012, 53, 915-919.	0.6	33
32	Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2710-2719.	0.8	32
33	Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 687-693.	0.2	29
34	Maintenance with 5-Azacitidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. <i>Blood</i> , 2018, 132, 971-971.	0.6	29
35	Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. <i>Cancer</i> , 2016, 122, 3831-3837.	2.0	27
36	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.	3.3	27

#	ARTICLE	IF	CITATIONS
37	Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2012, 53, 1525-1529.	0.6	26
38	Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2159-2164.	2.0	26
39	Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. <i>American Journal of Hematology</i> , 2012, 87, 272-276.	2.0	25
40	Symptom Burden of Busulfan + Melphalan Versus Melphalan Alone for Multiple Myeloma. <i>Blood</i> , 2014, 124, 1277-1277.	0.6	25
41	Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 285-292.	2.0	24
42	Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2019, 54, 839-848.	1.3	24
43	Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma—type Richter syndrome. <i>Blood Advances</i> , 2021, 5, 3528-3539.	2.5	24
44	Significance of Persistent Cytogenetic Abnormalities on Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 214-220.	2.0	23
45	Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. <i>Lancet Haematology</i> , 2018, 5, e532-e542.	2.2	23
46	Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1405-1412.	2.0	22
47	Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2197-2203.	2.0	22
48	Sweet Syndrome Associated with Furosemide. <i>Southern Medical Journal</i> , 2005, 98, 570-572.	0.3	22
49	The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e1-e5.	0.2	21
50	Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 665-671.	2.0	21
51	Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. <i>American Journal of Hematology</i> , 2019, 94, 1382-1387.	2.0	20
52	Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. <i>Bone Marrow Transplantation</i> , 2019, 54, 1089-1093.	1.3	20
53	Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 335-342.	2.0	20
54	High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. <i>Lancet Haematology</i> , 2017, 4, e283-e292.	2.2	19

#	ARTICLE	IF	CITATIONS
55	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 269-277.	2.0	19
56	Chimeric antigen receptor T-cell therapy toxicities. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2414-2424.	1.1	19
57	Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). <i>Bone Marrow Transplantation</i> , 2022, 57, 51-56.	1.3	19
58	A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1453-1458.	2.0	18
59	Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. <i>European Journal of Haematology</i> , 2017, 99, 532-535.	1.1	18
60	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	2.5	18
61	Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 430.e1-430.e7.	0.6	18
62	Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 560-569.	0.2	17
63	Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. <i>Cancer</i> , 2020, 126, 2183-2192.	2.0	17
64	Epigenetic therapy in allogeneic hematopoietic stem cell transplantation. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2013, 35, 126-33.	0.7	17
65	Improved Progression-Free Survival with Minimal Toxicity after Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Hematological Malignancy. <i>Blood</i> , 2014, 124, 2533-2533.	0.6	17
66	Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. <i>American Journal of Hematology</i> , 2016, 91, E442-7.	2.0	16
67	Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 197-203.	2.0	16
68	Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. <i>Blood Advances</i> , 2022, 6, 920-930.	2.5	16
69	Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 961-965.	2.0	15
70	Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 226-231.	2.0	15
71	High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. <i>Leukemia and Lymphoma</i> , 2019, 60, 442-452.	0.6	15
72	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. <i>Cancer</i> , 2021, 127, 82-92.	2.0	15

#	ARTICLE	IF	CITATIONS
73	Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 581-587.	2.0	14
74	Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. <i>Cancer</i> , 2017, 123, 2661-2670.	2.0	14
75	Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. <i>Haematologica</i> , 2021, 106, 1988-1990.	1.7	14
76	HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. <i>Current Research in Translational Medicine</i> , 2019, 67, 51-55.	1.2	13
77	Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. <i>Haematologica</i> , 2021, 106, 3211-3214.	1.7	13
78	Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 533-535.	0.6	12
79	Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 122-128.	0.2	12
80	Phase I/IIb Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2014, 124, 33-33.	0.6	12
81	Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. <i>Cancer</i> , 2017, 123, 3568-3575.	2.0	11
82	Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 126-135.	1.2	11
83	Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years. <i>Leukemia and Lymphoma</i> , 2019, 60, 3536-3543.	0.6	11
84	Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1039-1044.	2.0	11
85	Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. <i>Blood Advances</i> , 2020, 4, 4834-4837.	2.5	11
86	Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. <i>Bone Marrow Transplantation</i> , 2021, 56, 2005-2012.	1.3	11
87	Ex Vivo Fucosylation Of Cord Blood Accelerates Neutrophil and Platelet Engraftment. <i>Blood</i> , 2013, 122, 691-691.	0.6	11
88	Eltrombopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Double Blind Placebo Controlled Trial. <i>Blood</i> , 2015, 126, 738-738.	0.6	11
89	Unrelated Donor Transplantation for Acute Myelogenous Leukemia in First Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1067-1071.	2.0	10
90	Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 6781-6787.	3.2	10

#	ARTICLE	IF	CITATIONS
91	Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1003.e1-1003.e13.	0.6	10
92	Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2012, 120, 4082-4082.	0.6	10
93	Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. <i>European Journal of Haematology</i> , 2016, 97, 342-347.	1.1	9
94	Comparative Safety, Bioavailability, and Pharmacokinetics of Oral Dexamethasone, 4-mg and 20-mg Tablets, in Healthy Volunteers Under Fasting and Fed Conditions: A Randomized Open-label, 3-way Crossover Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 768-773.	0.2	9
95	Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e221-e238.	0.2	9
96	Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Cancer</i> , 2021, 127, 1598-1605.	2.0	9
97	A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. <i>Blood</i> , 2022, 139, 1289-1301.	0.6	9
98	Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. <i>Blood</i> , 2015, 126, 3155-3155.	0.6	9
99	Umbilical cord blood transplantation. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 786-801.	0.3	9
100	Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. <i>Blood</i> , 2017, 129, 3031-3033.	0.6	8
101	Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells. <i>Experimental Hematology</i> , 2020, 81, 32-41.	0.2	8
102	Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. <i>British Journal of Haematology</i> , 2021, 193, 1004-1008.	1.2	8
103	Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2012, 120, 4081-4081.	0.6	8
104	Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. <i>Leukemia and Lymphoma</i> , 2022, 63, 710-721.	0.6	8
105	Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1905-1912.	0.6	7
106	Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1340-1346.	2.0	7
107	Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. <i>Blood Advances</i> , 2020, 4, 1296-1306.	2.5	7
108	Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation. <i>Blood</i> , 2016, 128, 4548-4548.	0.6	7



#	ARTICLE	IF	CITATIONS
109	KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. <i>Bone Marrow Transplantation</i> , 2022, 57, 1142-1149.	1.3	7
110	Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. <i>Transfusion</i> , 2017, 57, 1052-1057.	0.8	6
111	Establishing an autologous versus allogeneic hematopoietic cell transplant program in nations with emerging economies. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 173-177.	0.6	6
112	Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. <i>European Journal of Haematology</i> , 2017, 98, 263-268.	1.1	6
113	Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. <i>Annals of Hematology</i> , 2019, 98, 2233-2235.	0.8	6
114	Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. <i>Haematologica</i> , 2019, 104, e555-e557.	1.7	6
115	Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 913.e1-913.e12.	0.6	6
116	Safety Analysis of Intra-Patient Dose- Study of Crenolanib Maintenance Therapy in Patients with FLT3 Mutant AML Following Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2018, 132, 3426-3426.	0.6	6
117	Autologous Stem Cell Transplantation in Waldenström's Macroglobulinemia. <i>Blood</i> , 2012, 120, 4533-4533.	0.6	6
118	Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study. <i>Blood</i> , 2015, 126, 929-929.	0.6	6
119	Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 395.e1-395.e11.	0.6	6
120	Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1413-1417.	2.0	5
121	Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 36-42.	0.2	5
122	Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. <i>Quality of Life Research</i> , 2018, 27, 979-985.	1.5	5
123	Melphalan-based autologous transplant in octogenarian multiple myeloma patients. <i>American Journal of Hematology</i> , 2019, 94, E2-E5.	2.0	5
124	Haploidentical transplants for patients with graft failure after the first allograft. <i>American Journal of Hematology</i> , 2020, 95, E267.	2.0	5
125	Update of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 46-47.	0.6	5
126	Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia. <i>Blood</i> , 2013, 122, 5356-5356.	0.6	5



#	ARTICLE	IF	CITATIONS
127	Development of Donor Cell Derived Leukemia After Allogeneic Stem Cell Transplant. <i>Blood</i> , 2013, 122, 2083-2083.	0.6	5
128	Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. <i>Leukemia and Lymphoma</i> , 2010, 51, 1478-1484.	0.6	4
129	A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. <i>Leukemia and Lymphoma</i> , 2018, 59, 515-518.	0.6	4
130	Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. <i>American Journal of Hematology</i> , 2018, 94, E72-E74.	2.0	4
131	Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1347-1354.	2.0	4
132	When should transplant physicians think about familial blood cancers?. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e68.	0.6	4
133	Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1077-1083.	2.0	4
134	Melphalan-Based Autologous Transplantation in the Octogenarian Multiple Myeloma Patient Population. <i>Blood</i> , 2018, 132, 4608-4608.	0.6	4
135	Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2010, 116, 1948-1948.	0.6	4
136	Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90yttrium Ibritumomab Tiuxetan (90YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results. <i>Blood</i> , 2011, 118, 662-662.	0.6	4
137	Plasmablastic Lymphoma: 28 Patient Single Institution Experience. <i>Blood</i> , 2013, 122, 4310-4310.	0.6	4
138	Feasibility of a Smartphone-Based Health Coaching Intervention for Patient Self-Management of Nutrition in the Post-Chemotherapy Setting. <i>Blood</i> , 2016, 128, 3554-3554.	0.6	4
139	Treatment of AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Low-Dose Azacitidine (AZA).. <i>Blood</i> , 2010, 116, 3445-3445.	0.6	4
140	Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience,. <i>Blood</i> , 2011, 118, 4118-4118.	0.6	4
141	Symptom Burden of Busulfan and Melphalan Versus Melphalan Alone for Multiple Myeloma. <i>Blood</i> , 2017, 130, 681-681.	0.6	4
142	Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 1277-1284.	3.2	4
143	Melphalan Dose Intensity for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S21.	2.0	3
144	Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. <i>British Journal of Haematology</i> , 2021, 192, e115-e120.	1.2	3

#	ARTICLE	IF	CITATIONS
145	Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. <i>British Journal of Haematology</i> , 2021, 193, e23-e26.	1.2	3
146	Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 404.e1-404.e5.	0.6	3
147	Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. <i>Clinical Cancer Research</i> , 2021, 27, 5847-5856.	3.2	3
148	Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity score matched analysis. <i>American Journal of Hematology</i> , 2021, 96, E455-E457.	2.0	3
149	Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls. <i>Blood</i> , 2019, 134, 700-700.	0.6	3
150	Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma. <i>Blood</i> , 2013, 122, 1983-1983.	0.6	3
151	In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials. <i>Blood</i> , 2015, 126, 3192-3192.	0.6	3
152	Safety and Feasibility of Administration of High Doses of Ex Vivo Expanded NK Cells for Prevention of Disease Relapse after Transplantation for Patients with Myeloid Malignancies - Final Results of a Phase I Clinical Trial. <i>Blood</i> , 2016, 128, 500-500.	0.6	3
153	Gene Expression Profiling Predicts Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. <i>Blood</i> , 2016, 128, 5628-5628.	0.6	3
154	Salvage Autologous or Allogeneic Stem Cell Transplantation After the Failure of First Autograft in Patients with Multiple Myeloma.. <i>Blood</i> , 2009, 114, 1186-1186.	0.6	3
155	Reducing Gastrointestinal Toxicity Associated with Autologous Transplantation for Multiple Myeloma without Compromising Its Anti-Myeloma Effect. <i>Blood</i> , 2017, 130, 680-680.	0.6	3
156	A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan±clofarabine in allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 0, , .	1.3	3
157	Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. <i>Acta Haematologica</i> , 2021, 144, 74-81.	0.7	2
158	Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis. <i>Blood</i> , 2019, 134, 42-42.	0.6	2
159	Allogeneic Stem Cell Transplantation for CML in Second Chronic Phase After Blast Crisis in the Tyrosine Kinase Inhibitor Era. <i>Blood</i> , 2011, 118, 2039-2039.	0.6	2
160	Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma. <i>Blood</i> , 2012, 120, 75-75.	0.6	2
161	Characteristics Of Multiple Myeloma Patients With 6-Year Or Longer Progression-Free Survival After a Single Autologous Transplant. <i>Blood</i> , 2013, 122, 3366-3366.	0.6	2
162	Myeloablative Timed Sequential Busulfan Is Safe in Older Patients. <i>Blood</i> , 2014, 124, 3859-3859.	0.6	2

#	ARTICLE	IF	CITATIONS
163	Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation. <i>Blood</i> , 2015, 126, 152-152.	0.6	2
164	Post-Transplantation High Dose Cyclophosphamide As Gvhd Prophylaxis in 9/10 HLA-Matched Unrelated Donors Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 3135-3135.	0.6	2
165	Outcome of Autologous Stem Cell Transplantation in Myeloma Patients Aged ≥ 75 Years. <i>Blood</i> , 2016, 128, 3453-3453.	0.6	2
166	Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma.. <i>Blood</i> , 2010, 116, 4569-4569.	0.6	2
167	Haploidentical Transplantation For Patients With Advanced Hematologic Malignancies With Melphalan-Based Conditioning – Interim Results From a Phase II Clinical Trial. <i>Blood</i> , 2013, 122, 4523-4523.	0.6	2
168	Disease Characteristics of Multiple Myeloma Involving BRAF Mutations. <i>Blood</i> , 2021, 138, 4755-4755.	0.6	2
169	Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. <i>Blood</i> , 2021, 138, 482-482.	0.6	2
170	Phase II study of umbilical cord blood–derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM).. <i>Journal of Clinical Oncology</i> , 2022, 40, 8009-8009.	0.8	2
171	Autologous Hematopoietic Stem Cell Transplantation in Light Chain Amyloidosis (AL) With Renal Involvement. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S234-S235.	2.0	1
172	Outcome of Patients with Multiple Myeloma by Ethnicity in the Setting of Autologous Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S231-S232.	2.0	1
173	Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S40-S41.	2.0	1
174	Validation of a Predictive Model for Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome Receiving Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S107.	2.0	1
175	Advancement in monoclonal antibody therapy for multiple myeloma. <i>Lancet Haematology</i> , 2020, 7, e354-e355.	2.2	1
176	Peripheral Blood Stem Cell Mobilization for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Growth Factors Only Vs. Growth Factors + Chemotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S286-S287.	2.0	1
177	Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S6-S7.	2.0	1
178	Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 243.e1-243.e6.	0.6	1
179	Is a Matched Unrelated Donor Search Needed for All Allogeneic Transplant Candidates?. <i>Blood</i> , 2018, 132, 3450-3450.	0.6	1
180	Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. <i>Blood</i> , 2019, 134, 3296-3296.	0.6	1

#	ARTICLE	IF	CITATIONS
181	Outcomes of Lenalidomide Retreatment with Novel Triplet Regimens in Multiple Myeloma Patients Progressing on Lenalidomide-Based Maintenance Therapy: A Single Center Retrospective Analysis. Blood, 2019, 134, 3198-3198.	0.6	1
182	Treatment of FLT3-ITD Positive AML Relapsing After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) with Sorafenib.. Blood, 2010, 116, 3471-3471.	0.6	1
183	Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Blood, 2011, 118, 333-333.	0.6	1
184	EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma.. Blood, 2012, 120, 3094-3094.	0.6	1
185	Vorinostat (SAHA) Combined With High-Dose Gemcitabine/Busulfan/Melphalan (SAHA/Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Patients With Refractory Lymphomas. Blood, 2013, 122, 2095-2095.	0.6	1
186	Transplant Outcomes of 9/10 HLA Matched Unrelated Donors (MUD) Treated with Post-Transplant Cyclophosphamide for Prevention of Graft Versus Host Disease. Blood, 2014, 124, 2486-2486.	0.6	1
187	Clinical Characteristics and Outcomes in Patients with Multiple Myeloma and CKS1B Gene Gain/Amplification after Autologous Stem Cell Transplantation. Blood, 2014, 124, 2521-2521.	0.6	1
188	Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant. Blood, 2015, 126, 3194-3194.	0.6	1
189	Minimal Residual Disease Detected By Multiparameter Flow Cytometry and Complex Karyotype Are the Major Prognostic Factors for Relapse after HCT. Blood, 2015, 126, 4342-4342.	0.6	1
190	Phase I/II Trial of Lenalidomide and High-Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma: Updated Results. Blood, 2016, 128, 2269-2269.	0.6	1
191	Durable Remission and Survival in Relapsed/Refractory Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 5884-5884.	0.6	1
192	Response Before Autologous Hematopoietic Stem Cell Transplantation Is An Important Predictor of Outcome in Multiple Myeloma,. Blood, 2011, 118, 4119-4119.	0.6	1
193	Increased Bone Marrow Plasma Cell Infiltration Pre-Transplant Is Associated with Worse Outcomes in Patients Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation for Multiple Myeloma,. Blood, 2011, 118, 4135-4135.	0.6	1
194	Role of Serum Lactate Dehydrogenase (LDH) As a Prognostic Marker for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. Blood, 2012, 120, 3115-3115.	0.6	1
195	Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis. Blood, 2013, 122, 3349-3349.	0.6	1
196	A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS. Blood, 2019, 134, 257-257.	0.6	1
197	Maintenance Therapy with Ipilimumab Plus Lenalidomide after Autologous Stem Cell Transplantation for Patients with Lymphoma. Blood, 2020, 136, 9-11.	0.6	1
198	African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. Blood, 2020, 136, 9-10.	0.6	1

#	ARTICLE	IF	CITATIONS
199	Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 24-25.	0.6	1
200	Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 307.e1-307.e8.	0.6	1
201	Multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic transplantation for high-risk multiple myeloma: Results of the BMT CTN 1302 Trial. <i>Transplantation and Cellular Therapy</i> , 2022, , .	0.6	1
202	Safety and Efficacy of Non-Myeloablative (NMA) Melphalan-Based Conditioning for Haploidentical Allogeneic Stem Cell Transplantation (HaploSCT) in Patients with Advanced Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S195-S196.	2.0	0
203	Outcome of Patients with Systemic Light Chain (AL) Amyloidosis with Concurrent Renal and Cardiac Involvement. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S130.	2.0	0
204	Myeloablative Timed Sequential Busulfan Is Safe in Patients with Relapsed or High-Risk Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S228-S229.	2.0	0
205	Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S289-S290.	2.0	0
206	A Case Control Study of Syngeneic Transplantation Versus Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e8.	0.2	0
207	Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e138-e139.	0.2	0
208	Transplant Outcomes for Patients with Secondary Acute Myeloid Leukemia (AML) Arising From Myeloproliferative Neoplasms (MPN). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S322-S323.	2.0	0
209	Stability of Captisol-Enabled Melphalan (Evomela) in 0.9% Sodium Chloride Solution in IV Bags and Glass Vials at Room Temperature and Refrigeration. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S287.	2.0	0
210	Myeloablative Conditioning Using Timed Sequential Busulfan in Older Patients with Acute Myeloid Leukemia: Long Term Results of a Prospective Phase II Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S116-S117.	2.0	0
211	Comparison of Tacrolimus and Post-Transplant Cyclophosphamide (PTCy) with Tacrolimus and Methotrexate (Tac/MTX) Gvhd Prophylaxis in Patients with AML Undergoing Transplantation from Matched Related or Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S235-S236.	2.0	0
212	Impact of cytogenetics versus FISH detected t(11;14) in newly diagnosed multiple myeloma patients with upfront transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e218-e219.	0.2	0
213	Depth of Response and Outcomes by Initial Therapy Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e298-e299.	0.2	0
214	Comparison of Post-Transplant Cyclophosphamide and Tacrolimus and Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S125.	2.0	0
215	Conditioning with Busulfan Plus Melphalan (Bu-Mel) Results in More Prolonged Progression-Free Survival (PFS) Versus Melphalan (Mel) Alone before Autologous Stem Cell Transplantation (auto-HCT) in Patients with High-Risk Multiple Myeloma (MM): Long-Term Results of a Randomized, Phase 3 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S241-S242.	2.0	0
216	Pegfilgrastim in Autoimmune Neutropenia.. <i>Blood</i> , 2004, 104, 3790-3790.	0.6	0



#	ARTICLE	IF	CITATIONS
217	B-Type Natriuretic Peptide (BNP) and Mitral Velocity E/A Ratio (MV E/A) Are Two Important Noninvasive Functional Indices of Cardiac AL Amyloidosis.. Blood, 2007, 110, 4773-4773.	0.6	0
218	Role of MicroRNAs in Resistance to Dexamethasone in Multiple Myeloma Cell Lines. Blood, 2008, 112, 3680-3680.	0.6	0
219	Outcome of High Dose Melphalan with Autologous Hematopoietic Stem Cell Transplant In Myeloma Associated with AL Amyloidosis. Blood, 2010, 116, 2400-2400.	0.6	0
220	Autologous Hematopoietic Cell Transplantation In Multiple Myeloma Patients Age 70 Years and Older.. Blood, 2010, 116, 4576-4576.	0.6	0
221	High Dose Melphalan with Autologous Stem Cell Transplantation Overcomes Poor Prognosis of Primary Amyloidosis. Blood, 2010, 116, 1350-1350.	0.6	0
222	A Randomized Phase II Trial of Fludarabine/Melphalan 140 Vs Fludarabine/ Melphalan 100 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma,. Blood, 2011, 118, 4108-4108.	0.6	0
223	High-Dose Infusional Gemcitabine (Gem) Combined with Busulfan (Bu) and Melphalan (Mel) (GemBuMel) with Autologous Stem-Cell Transplant (ASCT) in Patients with Refractory Lymphoid Malignancies. Blood, 2011, 118, 3083-3083.	0.6	0
224	A Comparative Study of the Outcome of High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation in Patients with High-Risk or Standard-Risk Myeloma Treated Concurrently,. Blood, 2011, 118, 4156-4156.	0.6	0
225	Durable Responses with Autologous Hematopoietic Stem Cell Transplantation in Patients with POEMS Syndrome. Blood, 2011, 118, 4522-4522.	0.6	0
226	Survival Disparities Between African-American and Caucasian Patients Treated with Autologous Stem Cell Transplantation for Multiple Myeloma Are Eliminated in the Era of Novel Therapeutics. Blood, 2011, 118, 2017-2017.	0.6	0
227	Bortezomib and BEAM-Rituximab Reduced-Intensity Conditioning for High-Risk Lymphoma Patients Who Are Not Eligible for Nonmyeloablative Allogeneic Stem Cell Transplantation. Blood, 2012, 120, 4157-4157.	0.6	0
228	Comparative Analysis of the Value of Consolidation with Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Versus High-Dose Cytarabine (HDAC) Based Chemotherapy in Patients (pts) with Acute Myeloid Leukemia (AML) with Chromosome Seven Abnormalities. Blood, 2012, 120, 2029-2029.	0.6	0
229	Feasibility of Hematopoietic Stem Cell Collection and Cryopreservation in Waldenstrom's Macroglobulinemia. Blood, 2012, 120, 4128-4128.	0.6	0
230	International Consensus Criteria for Tyrosine Kinase Inhibitor Response and Outcome of Allogeneic Stem Cell Transplantation for CML. Blood, 2012, 120, 1997-1997.	0.6	0
231	Cardiac Toxicity After High-Dose Melphalan and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Blood, 2012, 120, 2027-2027.	0.6	0
232	High Dose Therapy Improves Survival in Systemic Light Chain Amyloidosis: 14 Year Follow up. Blood, 2012, 120, 750-750.	0.6	0
233	Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2013, 31, 7010-7010.	0.8	0
234	Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblastic Leukemia (ALL) With First Complete Remission (CR). Blood, 2013, 122, 2142-2142.	0.6	0



#	ARTICLE	IF	CITATIONS
235	Outcomes Among High Risk and Standard Risk Multiple Myeloma Patients Treated With High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 3358-3358.	0.6	0
236	The Effect Of CMV Reactivation On Relapse and Survival In Patients With AML and MDS After Allogeneic Stem Cell Transplant (allo-HCT). <i>Blood</i> , 2013, 122, 4531-4531.	0.6	0
237	Bortezomib With High-Dose Melphalan, Arsenic Trioxide, and Ascorbic Acid In a Preparative Regimen For Multiple Myeloma: 5-Year Follow Up. <i>Blood</i> , 2013, 122, 5547-5547.	0.6	0
238	Autologous Stem Cell Transplantation Improves Survival For High Risk Cardiac Amyloidosis. <i>Blood</i> , 2013, 122, 3341-3341.	0.6	0
239	High-Dose Gemcitabine Combined With Busulfan and Melphalan (Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Refractory and Relapsed Myeloma. <i>Blood</i> , 2013, 122, 3346-3346.	0.6	0
240	Pure Red Cell Aplasia In Major ABO Mismatched Allogeneic Hematopoietic Cell Transplantation Is Associated With Severe Pancytopenia. <i>Blood</i> , 2013, 122, 5449-5449.	0.6	0
241	Autologous stem cell transplantation in dialysis-dependent myeloma patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8601-8601.	0.8	0
242	Randomized phase III trial of busulfan plus melphalan versus melphalan alone for multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8538-8538.	0.8	0
243	Phase I/II Trial of Lenalidomide and High Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma. <i>Blood</i> , 2014, 124, 3981-3981.	0.6	0
244	Assessment of Incidence Toxoplasma Gondii Infection and Outcomes in Allogeneic Stem Cell Patients. <i>Blood</i> , 2014, 124, 1187-1187.	0.6	0
245	Effect of Timing and Duration of Maintenance Lenalidomide in Myeloma Patients after Autologous Stem Cell Transplantations. <i>Blood</i> , 2014, 124, 194-194.	0.6	0
246	Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results. <i>Blood</i> , 2015, 126, 4376-4376.	0.6	0
247	Outcomes of Haploidentical Stem Cell Transplants for De Novo Acute Myeloid Leukemia, Myelodysplastic Syndrome and Acute Myeloid Leukemia Arising from MDS: The MD Anderson Experience. <i>Blood</i> , 2015, 126, 3225-3225.	0.6	0
248	Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma. <i>Blood</i> , 2015, 126, 1992-1992.	0.6	0
249	Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. <i>Blood</i> , 2015, 126, 5390-5390.	0.6	0
250	Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. <i>Blood</i> , 2016, 128, 3314-3314.	0.6	0
251	Outcome of Autologous Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 4626-4626.	0.6	0
252	Comparable Outcomes of Therapy-Related and De Novo Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 2276-2276.	0.6	0

#	ARTICLE	IF	CITATIONS
253	A Case Control Study of Syngeneic Transplantation Versus Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson. <i>Blood</i> , 2016, 128, 4613-4613.	0.6	0
254	Hematopoietic Stem Cell Transplantation with Reduced Intensity Conditioning in Older Patients with Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 5847-5847.	0.6	0
255	Patient-Reported Outcomes and Patient-Performed Testing in Measuring Functional Impairment after Stem Cell Transplant in Patients with Multiple Myeloma. <i>Blood</i> , 2016, 128, 538-538.	0.6	0
256	Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 2144-2144.	0.6	0
257	Durability Results of Non-Myeloablative (NMA) Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed Follicular Lymphoma: 17- Year Experience. <i>Blood</i> , 2018, 132, 4651-4651.	0.6	0
258	Outcome of Autologous Stem Cell Transplantation in Waldenström's Macroglobulinemia. <i>Blood</i> , 2018, 132, 2149-2149.	0.6	0
259	Influence of the Intensity of the Conditioning Regimens on the Risks of Gvhd in Patients Receiving Rituximab Prophylaxis during Allogeneic Stem Cell Transplantation (alloSCT). <i>Blood</i> , 2018, 132, 4584-4584.	0.6	0
260	Long-Term Durable Responses after Autologous Stem Cell Transplantation in POEMS Syndrome. <i>Blood</i> , 2018, 132, 4606-4606.	0.6	0
261	Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. <i>Blood</i> , 2018, 132, 4607-4607.	0.6	0
262	Hematopoietic Cell Transplant-Composite Risk (HCT-CR) – a Novel Prognostic Model to Predict Transplant Outcomes. <i>Blood</i> , 2018, 132, 2141-2141.	0.6	0
263	Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 2021-2021.	0.6	0
264	Post-Transplant Cyclophosphamide (PT-Cy) Based Haploidentical Cell Transplantation (Haplo) Versus Rabbit Anti-Thymocyte Globulin (r-ATG) Based HLA Matched Unrelated Donor (MUD) Transplantation in Patients (pts) with Relapsed/Refractory Lymphoma. <i>Blood</i> , 2019, 134, 4530-4530.	0.6	0
265	Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantation (ASCT) for Patients (pts) with Relapsed Follicular Lymphoma (FL). <i>Blood</i> , 2019, 134, 322-322.	0.6	0
266	Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 512-512.	0.6	0
267	Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. <i>Blood</i> , 2021, 138, 1802-1802.	0.6	0
268	Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 1779-1779.	0.6	0
269	Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Post-Transplant Myeloma Patients. <i>Blood</i> , 2021, 138, 4774-4774.	0.6	0
270	A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2021, 138, 3941-3941.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Outcomes in Patients with AL (Light-Chain) Cardiac Amyloidosis. Blood, 2020, 136, 11-13.	0.6	0
272	PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy. Blood, 2020, 136, 6-7.	0.6	0
273	Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 18-19.	0.6	0
274	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 22-22.	0.6	0
275	Autologous Vs. Allogeneic Stem Cell Transplantation in Double-Expressor Lymphoma. Blood, 2020, 136, 24-25.	0.6	0
276	Trial in Progress: A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule(s) and Dose(s) of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 37-38.	0.6	0
277	Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies. Blood, 2020, 136, 10-12.	0.6	0
278	Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 20-21.	0.6	0
279	Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial. Blood, 2020, 136, 10-11.	0.6	0
280	Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance. Blood, 2020, 136, 14-15.	0.6	0
281	Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. Blood, 2020, 136, 23-24.	0.6	0
282	A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS. Blood, 2020, 136, 37-38.	0.6	0
283	P-197: Central nervous system Multiple Myeloma (CNS-MM), presentation and outcomes in an Era of anti-CD38 and pomalidomide inclusive therapies. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S146.	0.2	0
284	Stability of Captisol-enabled versus propylene glycol-based melphalan at room temperature and after refrigeration. American Journal of Health-System Pharmacy, 2022, , .	0.5	0
285	Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Transplantation and Cellular Therapy, 2022, 28, S83-S84.	0.6	0
286	KRD vs. VRD as Induction before Autologous Hematopoietic Progenitor Cell Transplantation for High-Risk Newly Diagnosed Multiple Myeloma. Transplantation and Cellular Therapy, 2022, 28, S406-S407.	0.6	0
287	Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, S404-S405.	0.6	0
288	Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. Transplantation and Cellular Therapy, 2022, 28, S82-S83.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Captisol-Enabled Melphalan (Evomela) Pharmacokinetics between Short and Long Infusion Arms in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S461-S462.	0.6	0
290	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 264.e1-264.e9.	0.6	0
291	Lenalidomide: Based maintenance after autologous hematopoietic stem cell transplant for patients with high-risk multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20024-e20024.	0.8	0